The filing is routine and small in scale relative to market cap. Monitor for any acceleration of insider selling patterns, but this single filing does not signal a change in fundamentals.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $15.95entry
- T+1 · 12d ago −6.96%α −2.55% · $14.84
- T+5 · 6d ago +2.38%α +3.30% · $16.33
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Christine Ring, an officer of Nurix Therapeutics, filed a Form 144 notice of intent to sell 6,113 shares of common stock, with an estimated aggregate market value of approximately $157,104. The filing also discloses four prior 10b5-1 plan sales executed between September and November 2026, totaling 22,175 shares. This is a routine insider sale under a pre-arranged trading plan, representing a small fraction of the company's $3.0B market cap.
Key Facts
- Christine Ring, an officer, filed Form 144 to sell 6,113 shares of common stock.
- Estimated aggregate market value of the proposed sale is $157,104.10.
- The filing also reports four prior 10b5-1 plan sales from September to November 2026 totaling 22,175 shares.
- The proposed sale represents about 0.005% of the company's $3.0B market cap.
- The filing is an advance notice of intent to sell; the sale may not occur.
Financial Impact
Proposed sale of 6,113 shares valued at ~$157K, or ~0.005% of market cap.
Risk Factors
- Insider selling under a 10b5-1 plan is pre-arranged and not necessarily indicative of negative sentiment.
- The filing is an intent to sell; the actual sale may not be executed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010618 |
| Document: 0001950047-26-010618-index.html | 0001950047-26-010618 |
| Document: 0001950047-26-010618.txt | 0001950047-26-010618 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Viewing Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers